Rockwell Medical price to sales ratio RMTI

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026: 0.4×
10-year median: 1.0×
Against its 10-year history: 15th; percentile: 0 is its lowest day, 100 its highest
10-year range: 0.1× to 8.3×
Peer median: 0.4×

Rockwell Medical's price to sales ratio is 0.4× as of Oct 23, 2026.

That is below its ten-year median of 1.0×, lower than on 85% of days in the last ten years.

Over that time it ranged from 0.1× in Nov 2022 to 8.3× in Apr 2017.

The median for 4 large drugmakers of a similar size is 0.4×.

Price to sales ratio over time

median 1×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	0.4×	0.3×	0.6×
2025	0.5×	0.3×	0.8×
2024	0.7×	0.4×	1.5×
2023	0.7×	0.2×	1.0×
2022	0.2×	0.1×	0.7×
2021	0.6×	0.6×	2.6×
2020	1.5×	1.0×	3.6×
2019	2.4×	1.9×	5.2×
2018	2.3×	2.3×	5.8×
2017	5.4×	5.2×	8.3×
2016	6.2×	5.2×	9.2×
2015	9.4×	7.5×	16.4×
2014	7.0×	6.7×	11.0×
2013	8.6×	1.6×	11.9×
2012	3.5×	2.3×	4.5×

Against its peers

Companies in Drug Manufacturers - General nearest Rockwell Medical's size, closest first, today.

Company	Price to sales ratio
RMTIRockwell Medical	0.4×
ATNMActinium Pharmaceuticals	n/m
SPROSpero Therapeutics	1.4×
LFVNLifevantage	0.4×
NATRNatures Sunshine Products	0.4×
Peer median	0.4×

Where Rockwell Medical ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Rockwell Medical

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.